Patient characteristics (n = 14)
Characteristics . | Patients, n . |
---|---|
Median age (range), y | 59 (44-84) |
Male sex, n (%) | 11 (79) |
ECOGstatus, n (%) | |
0 | 2 (14) |
1 | 11 (79) |
2 | 1 (7) |
Primary histologic diagnosis | |
Enteropathy-associated T-cell lymphoma, type II | 1 |
γ-δ hepatosplenic T-cell lymphoma | 1 |
HTLV-1 associated adult T-cell leukemia/lymphoma | 1 |
Peripheral T-cell lymphoma, not otherwise specified | 3 |
Alk-negative anaplastic large cell lymphoma | 1 |
MF | 2 |
MF transformed to large cell lymphoma | 2 |
MF/SS | 2 |
Cutaneous γ-δ T-cell lymphoma | 1 |
Disease stage at study entry, n (%) | |
PTCL (n = 7) | |
Stage IV | 7 (100) |
CTCL (n = 7) | |
MF, stage IB | 2 (14) |
MF, stage IVA1 | 2 (14) |
MF transformed to large cell lymphoma, stage IV | 2 (14) |
Cutaneous γ-δ T-cell lymphoma, stage IV | 1 (7) |
Refractory to most recent therapy, n (%) | 14 (100) |
Median time from diagnosis to study entry (range), y | 4.4 (0.4-14.8) |
Median prior lines of therapy, n (range) | 4 (1-11) |
For MF patients (n = 6), prior systemic treatment, n (%) | |
Histone deacetylase inhibitor | 5 (83) |
Oral retinoid therapy | 6 (100) |
Oral methotrexate | 4 (67) |
Interferon | 3 (50) |
Chemotherapy | 5 (83) |
Total skin electron beam therapy | 4 (67) |
Denileukin diftitox | 1 (17) |
Alemtuzumab | 1 (17) |
Characteristics . | Patients, n . |
---|---|
Median age (range), y | 59 (44-84) |
Male sex, n (%) | 11 (79) |
ECOGstatus, n (%) | |
0 | 2 (14) |
1 | 11 (79) |
2 | 1 (7) |
Primary histologic diagnosis | |
Enteropathy-associated T-cell lymphoma, type II | 1 |
γ-δ hepatosplenic T-cell lymphoma | 1 |
HTLV-1 associated adult T-cell leukemia/lymphoma | 1 |
Peripheral T-cell lymphoma, not otherwise specified | 3 |
Alk-negative anaplastic large cell lymphoma | 1 |
MF | 2 |
MF transformed to large cell lymphoma | 2 |
MF/SS | 2 |
Cutaneous γ-δ T-cell lymphoma | 1 |
Disease stage at study entry, n (%) | |
PTCL (n = 7) | |
Stage IV | 7 (100) |
CTCL (n = 7) | |
MF, stage IB | 2 (14) |
MF, stage IVA1 | 2 (14) |
MF transformed to large cell lymphoma, stage IV | 2 (14) |
Cutaneous γ-δ T-cell lymphoma, stage IV | 1 (7) |
Refractory to most recent therapy, n (%) | 14 (100) |
Median time from diagnosis to study entry (range), y | 4.4 (0.4-14.8) |
Median prior lines of therapy, n (range) | 4 (1-11) |
For MF patients (n = 6), prior systemic treatment, n (%) | |
Histone deacetylase inhibitor | 5 (83) |
Oral retinoid therapy | 6 (100) |
Oral methotrexate | 4 (67) |
Interferon | 3 (50) |
Chemotherapy | 5 (83) |
Total skin electron beam therapy | 4 (67) |
Denileukin diftitox | 1 (17) |
Alemtuzumab | 1 (17) |
ECOG, Eastern Cooperative Oncology Group; MF, mycosis fungoides; SS, Sezary syndrome.